Journal of Shandong University (Health Sciences) ›› 2025, Vol. 63 ›› Issue (1): 99-107.doi: 10.6040/j.issn.1671-7554.0.2024.0935
• Clinical Research • Previous Articles
YUAN Zonghuai, PAN Guangye, CHI Yuemei, AN Chuanguo, ZHANG Yonggang
CLC Number:
[1] Zwimpfer TA, Tal O, Geissler F, et al. Low grade serous ovarian cancer-a rare disease with increasing therapeutic options[J]. Cancer Treat Rev, 2023, 112: 102497. doi: 10.1016/j.ctrv.2022.102497. [2] Montero-Macías R, Segura-Sampedro JJ, Rigolet R, et al. The role of systematic lymphadenectomy in low-grade serous ovarian cancer: a systematic review and Meta-analysis[J]. Cancers(Basel), 2024, 16(5): 955. doi: 10.3390/cancers16050955. [3] Kathleen IP, Karla JC, Marta LF, et al. High-throughput drug screening identifes novel therapeutics for low grade serous ovarian carcinoma[J]. Sci Data, 2024, 11(1):1024. doi: 10.1038/s41597-024-03869-x. [4] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. [5] Bao R, Qu H, Li B, et al. Knowledge mapping of immunotherapy for breast cancer: a bibliometric analysis from 2013 to 2022[J]. Hum Vaccin Immunother, 2024, 20(1): 2335728. doi: 10.1080/21645515.2024.2335728. [6] Öfverholm A, Törngren T, Rosén A, et al. Extended genetic analysis and tumor Characteristics in over 4600 women with suspected hereditary breast and ovarian cancer[J]. BMC Cancer, 2023, 23(1): 738. doi: 10.1186/s12885-023-11229-y. [7] Innella G, GodinoL, Erini G, et al. Factors predicting BRCA1/2 pathogenic variants in patients with ovarian cancer: a systematic review with meta-analysis[J]. J Clin Pathol, 2023, 76(8): 510-517. [8] Ottenbourgs T, Van NE. Novel endocrine therapeutic opportunities for estrogen receptor-positive ovarian cancer-what can we learn from breast cancer?[J]. Cancers(Basel), 2024, 16(10): 1862. doi: 10.3390/cancers16101862. [9] Smylie J, Rotondi MA, Filipenko S, et al. Randomized controlled trial demonstrates novel tools to assess patient outcomes of Indigenous cultural safety training[J]. BMC Med, 2024, 22(1): 3. doi: 10.1186/s12916-023-03193-y. [10] Birney E. Mendelian randomization[J]. Cold Spring Harb Perspect Med, 2022, 12(4): a041302. doi: 10.1101/cshperspect.a041302. [11] Fang A, Zhao Y, Yang P, et al. Vitamin D and human health: evidence from Mendelian randomization studies[J]. Eur J Epidemiol, 2024, 39(5): 467-490. [12] Davies NM, Holmes MV, Davey SG, et al. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians[J]. BMJ, 2018, 362: k601. doi: 10.1136/bmj.k601. [13] 李舒冉, 孙静, 孙绮悦, 等. 便秘与肺炎因果关系的双向孟德尔随机化分析[J].中国实验方剂学杂志, 2024, 30(23): 224-229. LI Shuran, SUN Jing, SUN Qiyue, et al. Bidirectional Mendelian randomization analysis of causal relationship between constipation and pneumonia[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2024, 30(23): 224-229. [14] Chen LL, Yang HQ, Li HT, et al. Insights into modifiable risk factors of cholelithiasis: a Mendelian randomization study[J]. Hepatology, 2022, 75(4): 785-796. [15] Pan SY, Zhang ZQ, Pang WY, et al. The causal relationship between bacterial pneumonia and diabetes: a two-sample mendelian randomization study[J]. Islets, 2024, 16(1): 2291885. doi: 10.1080/19382014.2023.2291885. [16] Cheng ZJ, Gao L, Huang P, et al. Genetic causal association between rheumatoid arthritis and periodontitis: a bidirectional two-sample Mendelian randomization analysis[J]. Clin Oral Investig, 2024, 28(1): 107. doi: 10.1007/s00784-024-05512-w. [17] Bowden J, Holmes MV. Meta-analysis and Mendelian randomization: a review[J]. Res Synth Methods, 2019, 10(4): 486-496. [18] Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method[J]. Eur J Epidemiol, 2017, 32(5): 377-389. [19] Bowden J, Davey SG, Haycock PC, et al. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator[J]. Genet Epidemiol, 2016, 40(4): 304-314. [20] Yin KJ, Huang JX, Wang P, et al. No genetic causal association between periodontitis and arthritis: a bidirectional twosample Mendelian randomization analysis[J]. Front Immunol, 2022, 13: 808832. doi: 10.3389/fimmu.2022.808832. [21] Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome[J]. Elife, 2018, 7: e34408. doi: 10.7554/eLife.34408. [22] Shu MJ, Li JR, Zhu YC, et al. Migraine and ischemic stroke: a mendelian randomization study[J]. Neurol Ther, 2022, 11(1): 237-246. [23] Jin Y, Yu X, Li J, et al. Causal effects and immune cell mediators between prescription analgesic use and risk of infectious diseases: a Mendelian randomization study[J]. Front Immunol, 2023, 14: 1319127. doi: 10.3389/fimmu.2023.1319127. [24] Babaier A, Mal H, Alselwi W, et al. Low-grade serous carcinoma of the ovary: the current status[J]. Diagnostics(Basel), 2022, 12(2): 458. doi: 10.3390/diagnostics12020458. [25] Si SH, Li JQ, Marlvin AT, et al. Identifying causality, genetic correlation, priority and pathways of large-scale complex exposures of breast and ovarian cancers[J]. Br J Cancer, 2021, 125(11): 1570-1581. [26] Marisa AV, Molly SD, Diana LU, et al. Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?[J]. Gynecol Oncol, 2011, 120(2): 229-232. [27] Shalaka J, Sridevi MN, Shylasree TS, et al. Synchronous and metachronous breast and ovarian cancers: experience from a single tertiary care cancer centre in India[J]. Indian J Surg Oncol, 2023, 14(4): 809-821. [28] Catherine SJ, Abigail F, Rodrigo A, et al. Breast cancer surveillance following ovarian cancer in BRCA mutation carriers[J]. Gynecol Oncol, 2022, 164(1): 202-207. [29] Perrone C, Angioli R, Luvero D, et al. Targeting BRAF pathway in low-grade serous ovarian cancer[J]. J Gynecol Oncol, 2024, 35(4): e104. doi: 10.3802/jgo.2024.35.e104. [30] Gershenson DM, Sun CC, Westin SN, et al. The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes[J]. Gynecol Oncol, 2022, 165(3): 560-567. [31] 张娜娜,赵一鸣,刘新敏,等.基于两样本孟德尔随机化探索子宫肌瘤与乳腺癌的因果关系[J].山东大学学报(医学版), 2023, 61(8): 86-93. ZHANG Nana, ZHAO Yiming, LIU Xinmin, et al.Causal relationgship between uterine leiomyomas and breast cancer:a two-sample Mendelian randomization study[J]. Journal of Shandog University(Health Sciences), 2023, 61(8): 86-93. [32] Kim YN, Chung YS, Park E, et al. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer[J]. Sci Rep, 2024, 14(1): 7992. doi: 10.1038/s41598-024-57515-y. [33] 中国抗癌协会肿瘤标志物专业委员会, 上海市抗癌协会肿瘤标志物专业委员会. 基于中国人群的BRCA胚系突变筛查专家共识(2024年版)[J]. 中国癌症杂志, 2024, 34(2): 220-238. China Anti-Cancer Association Tumor Biomarker Professional Committee, Shanghai Anti-Cancer Association Tumor Biomarker Professional Committee. Expert consensus on population-based BRCA germline mutation screening in China(2024 edition)[J]. China Oncology, 2024, 34(2): 220-238. [34] Emanuela DA, Iñigo E, Lara F, et al. Ovarian high-grade serous carcinoma with transitional-like(SET)morphology: a homologous recombination-deficient tumor[J]. Hum Pathol, 2023, 141: 15-21. doi: 10.1016/j.humpath.2023.08.010. |
[1] | YU Zhigang, ZHENG Chao. Current status, challenges and innovative approaches of multidisciplinary treatment for breast cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 1-9. |
[2] | . Shandong Province expert consensus on multidisciplinary treatment of breast cancer(2024 edition) [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 10-16. |
[3] | CHENG Yueqi, WANG Fei, YU Lixiang, ZHENG Chao, YU Zhigang. Progress in the study of trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 17-24. |
[4] | WANG Min, LI Xiping, TAN Jun, QIU Mei, HOU Zeyu, TIAN Ying, LUO Hongying, FAN Chaowen, QI Ling, YU Qi, XIE Wei. Lentivirus vector-mediated Gag-Caspase-8 induces apoptosis and S-phase arrest in triple-negative breast cancer primary cells [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 25-34. |
[5] | ZHANG Jie, ZHANG Fangfang, WANG Jingnan, LI Zeyu, SONG Ying, LI Na. Expression of circ_0000144 in breast cancer and its effect on the proliferation, migration and invasion ability of breast cancer cells [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 35-42. |
[6] | SONG Yawen, GUO Liantao, KONG Deguang, SUN Shengrong. VTCN1 causes poor prognosis and endocrine therapy resistance in HR+ breast cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 43-59. |
[7] | LIU Jingjing, PANG Jing, ZHAO Xiaodan, LIN Xin, FU Min, CHEN Jingjing. Machine learning model based on mammography and DCE-MRI to predict pathological complete response after neoadjuvant therapy in breast cancer: a dual center research [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 60-72. |
[8] | SUN Jing, YANG Ruimin, WANG Cong, ZHANG Yue, LUO Bing. Combined models based on preoperative ultrasound, inflammatory indicators and ultrasound radiomics for predicting axillary lymph node metastasis of breast cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 73-80. |
[9] | LI Yong, CUI Shujun, YANG Fei, ZHANG Fan, YIN Xiaoxia. Enhanced MRI-based subregional radiomics model can predict pathological complete response after neoadjuvant chemotherapy in breast cancer patients [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 81-89. |
[10] | LIU Xiangrong, ZHANG Xinsheng, YANG Jinran, YANG Xueyan, LIU Zhao, LIU Yinghua. Association of the ratio of ω-6/ω-3 polyunsaturated fatty acids with various tumor types risk: a systematic review and Meta-analysis [J]. Journal of Shandong University (Health Sciences), 2024, 62(8): 34-48. |
[11] | ZHANG Zhan, LI Jianfeng, LI Yanling, WANG Bowen, ANGWEN Chenglinlongzhu, WANG Xin, ZHANG Xiaoming, XIE Ping. Mendelian randomization analysis of causality between dietary factors and preeclampsia [J]. Journal of Shandong University (Health Sciences), 2024, 62(8): 59-66. |
[12] | FENG Yue, YU Yifan, WU Sijia, LI Hongkai, XUE Fuzhong. Mendelian randomization study of visceral adipose tissue and lung diseases [J]. Journal of Shandong University (Health Sciences), 2024, 62(7): 48-55. |
[13] | WU Tong, YANG Jingyu, LIN Dang, XU Wanru, ZENG Yujun. Genetic association of lipids and lipid-lowering drugs with chronic obstructive pulmonary disease based on Mendelian randomization [J]. Journal of Shandong University (Health Sciences), 2024, 62(5): 54-63. |
[14] | WU Fei, LI Qingli, XIAO Zhenwei. Causal association between cytokines and chronic kidney disease based on Mendelian randomization [J]. Journal of Shandong University (Health Sciences), 2024, 62(11): 85-95. |
[15] | ZHANG Nana, ZHAO Yiming, LIU Xinmin. Causal relationship between uterine leiomyomas and breast cancer: a two-sample Mendelian randomization study [J]. Journal of Shandong University (Health Sciences), 2023, 61(8): 86-93. |
Viewed | ||||||||||||||||||||||||||||||||||||||||||||||
Full text 94
|
|
|||||||||||||||||||||||||||||||||||||||||||||
Abstract 276
|
|
|||||||||||||||||||||||||||||||||||||||||||||
Cited |
|
|||||||||||||||||||||||||||||||||||||||||||||
Shared | ||||||||||||||||||||||||||||||||||||||||||||||
Discussed |
|